Community Acquired Pneumonia - Pipeline Review, H1 2019

Date: April 29, 2019
Pages: 148
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C49525CADFBEN
Leaflet:

Download PDF Leaflet

Community Acquired Pneumonia - Pipeline Review, H1 2019
Community Acquired Pneumonia - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H1 2019, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.

Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 1, 7, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase 0 stages comprises 1 molecules, respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Community Acquired Pneumonia - Overview
Community Acquired Pneumonia - Therapeutics Development
Community Acquired Pneumonia - Therapeutics Assessment
Community Acquired Pneumonia - Companies Involved in Therapeutics Development
Community Acquired Pneumonia - Drug Profiles
Community Acquired Pneumonia - Dormant Projects
Community Acquired Pneumonia - Discontinued Products
Community Acquired Pneumonia - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Community Acquired Pneumonia, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Community Acquired Pneumonia - Pipeline by Basilea Pharmaceutica Ltd, H1 2019
Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2019
Community Acquired Pneumonia - Pipeline by InflaRx NV, H1 2019
Community Acquired Pneumonia - Pipeline by ioGenetics Inc, H1 2019
Community Acquired Pneumonia - Pipeline by Iterum Therapeutics Plc, H1 2019
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2019
Community Acquired Pneumonia - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019
Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc, H1 2019
Community Acquired Pneumonia - Pipeline by Merck & Co Inc, H1 2019
Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics Plc, H1 2019
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, H1 2019
Community Acquired Pneumonia - Pipeline by ProThera Biologics Inc, H1 2019
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, H1 2019
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, H1 2019
Community Acquired Pneumonia - Dormant Projects, H1 2019
Community Acquired Pneumonia - Dormant Projects, H1 2019 (Contd..1), H1 2019
Community Acquired Pneumonia - Discontinued Products, H1 2019

LIST OF FIGURES

Number of Products under Development for Community Acquired Pneumonia, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

Basilea Pharmaceutica Ltd
Biotest AG
InflaRx NV
ioGenetics Inc
Iterum Therapeutics Plc
Kyorin Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Tetraphase Pharmaceuticals Inc
Wockhardt Ltd
Skip to top


Community Acquired Pneumonia - Pipeline Review, H2 2018 US$ 2,000.00 Jul, 2018 · 121 pages

Ask Your Question

Community Acquired Pneumonia - Pipeline Review, H1 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: